The burden of ovarian cancer in the USA from 2007 to 2018: evidence from the Medical Expenditure Panel Survey.

Autor:	Szamreta EA; Merck and Co., Inc., Rahway, NJ 07065, USA., Wang WJ; OPEN Health, Parsippany, NJ 07054, USA., Shah R; Daiichi Sankyo Inc., Basking Ridge, NJ 07920, USA., Corman S; PRECISIONheor, Bethesda, MD 20814, USA., Monberg M; Merck and Co., Inc., Rahway, NJ 07065, USA.
Jazyk:	angličtina
Zdroj:	Future oncology (London, England) [Future Oncol] 2023 Jun; Vol. 19 (19), pp. 1331-1342. Date of Electronic Publication: 2023 Jul 21.
DOI:	10.2217/fon-2022-1072
Abstrakt:	Aim: To evaluate the economic and humanistic burden of ovarian cancer in the USA. Methods: Medical Expenditure Panel Survey data (2007-2018) were used to estimate all-cause healthcare resource use and costs for economic burden and examine the activities of daily living and quality-of-life (QoL) measures for humanistic burden between ovarian cancer patients and a non-cancer population. Results: Compared with controls, patients with ovarian cancer had more comorbidities and worse QoL. Their predicted number of annual hospitalizations and office-based visits was significantly higher, as were their estimated annual all-cause total healthcare costs. Total costs were driven by hospitalization costs. Conclusion: The study identified the burden of ovarian cancer and demonstrated that patients with ovarian cancer have greater healthcare resource use, higher costs and worse QoL than the non-cancer population. Future research is needed to develop strategies for managing ovarian cancers and inform decision-making to reduce disease burden.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu